Endocannabinoid 2-arachidonoylglycerol self-administration by Sprague-Dawley rats and stimulation of in vivo dopamine transmission in the nucleus accumbens shell

Frontiers in Psychiatry

Volumn 5, Issue OCT, 2014, Pages

  De Luca, Maria Antonietta ^a,b   Valentini, Valentina ^a,b   Bimpisidis, Zisis ^a   Cacciapaglia, Fabio ^a   Caboni, Pierluigi ^a   di Chiara, Gaetano ^a,b,c  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b INN National Institute of Neuroscience   (Italy)

^c CNR   (Italy)

Author keywords

2 arachidonoilglycerol; Drug addiction; Endocannabinoids; In vivo microdialysis; Nucleus accumbens; Reward; Self administration

Indexed keywords

2 ARACHIDONOYLGLYCEROL; DOPAMINE; RIMONABANT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; IN VIVO STUDY; MALE; MICRODIALYSIS; NONHUMAN; NUCLEUS ACCUMBENS; RAT; REINFORCEMENT; REWARD; SELF ADMINISTRATION TEST;

EID: 84909951309     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2014.00140     Document Type: Article

References (79)

1. Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev (2006) 58(3):389-462. doi:10.1124/pr.58.3.2
2. Ahn K, Johnson DS, Cravatt BF. Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders. Expert Opin Drug Discov (2009) 4(7):763-84. doi:10.1517/17460440903018857
3. Di Marzo V. Endocannabinoids: synthesis and degradation. Rev Physiol Biochem Pharmacol (2008) 160:1-24. doi:10.1007/112_0505
4. Blankman JL, Cravatt BF. Chemical probes of endocannabinoid metabolism. Pharmacol Rev (2013) 65(2):849-71. doi:10.1124/pr.112.006387
5. Kirkham TC, Williams CM, Fezza F, Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol (2002) 136(4):550-7. doi:10.1038/sj.bjp.0704767
6. Piomelli D. More surprises lying ahead. The endocannabinoids keep us guessing. Neuropharmacology (2014) 76(Pt B):228-34. doi:10.1016/j.neuropharm.2013.07.026
7. Sugiura T, Kodaka T, Kondo S, Tonegawa T, Nakane S, Kishimoto S, et al. 2-Arachidonoylglycerol, a putative endogenous cannabinoid receptor ligand, induces rapid, transient elevation of intracellular free Ca2+ in neuroblastoma × glioma hybrid NG108-15 cells. Biochem Biophys Res Commun (1996) 229(1):58-64. doi:10.1006/bbrc.1996.1757
8. Gonsiorek W, Lunn C, Fan X, Narula S, Lundell D, Hipkin RW. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. Mol Pharmacol (2000) 57(5):1045-50.
9. Hillard CJ. Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol. Prostaglandins Other Lipid Mediat (2000) 61(1-2):3-18.
10. Sugiura T, Kobayashi Y, Oka S, Waku K. Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. Prostaglandins Leukot Essent Fatty Acids (2002) 66(2-3):173-92. doi:10.1054/plef.2001.0356
11. Alger BE, Kim J. Supply and demand for endocannabinoids. Trends Neurosci (2011) 34(6):304-15. doi:10.1016/j.tins.2011.03.003
12. Howlett AC, Reggio PH, Childers SR, Hampson RE, Ulloa NM, Deutsch DG. Endocannabinoid tone versus constitutive activity of cannabinoid receptors. Br J Pharmacol (2011) 163(7):1329-43. doi:10.1111/j.1476-5381.2011.01364.x
13. Lupica CR, Riegel AC, Hoffman AF. Marijuana and cannabinoid regulation of brain reward circuits. Br J Pharmacol (2004) 143(2):227-34. doi:10.1038/sj.bjp.0705931
14. Adermark L, Lovinger DM. Retrograde endocannabinoid signaling at striatal synapses requires a regulated postsynaptic release step. Proc Natl Acad Sci U S A (2007) 104(51):20564-9. doi:10.1073/pnas.0706873104
15. Howlett AC. Cannabinoid receptor signaling. Handb Exp Pharmacol (2005) 168:53-79. doi:10.1007/3-540-26573-2_2
16. Murataeva N, Straiker A, Mackie K. Parsing the players: 2-arachidonoylglycerol synthesis and degradation in the CNS. Br J Pharmacol (2014) 171(6):1379-91. doi:10.1111/bph.12411
17. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A (2002) 99(16):10819-24. doi:10.1073/pnas.152334899
18. Gulyas AI, Cravatt BF, Bracey MH, Dinh TP, Piomelli D, Boscia F, et al. Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. Eur J Neurosci (2004) 20(2):441-58. doi:10.1111/j.1460-9568.2004.03428.x
19. Long JZ, Nomura DK, Cravatt BF. Characterization of monoacylglycerol lipase inhibition reveals differences in central and peripheral endocannabinoid metabolism. Chem Biol (2009) 16(7):744-53. doi:10.1016/j.chembiol.2009.05.009
20. Blankman JL, Simon GM, Cravatt BF. A comprehensive profile of brain enzymesthat hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol (2007) 14(12):1347-56. doi:10.1016/j.chembiol.2007.11.006
21. Fu J, Bottegoni G, Sasso O, Bertorelli R, Rocchia W, Masetti M, et al. A catalytically silent FAAH-1 variant drives anandamide transport in neurons. Nat Neurosci (2012) 15(1):64-9. doi:10.1038/nn.2986
22. Maldonado R, Berrendero F, Ozaita A, Robledo P. Neurochemical basis of cannabis addiction. Neuroscience (2011) 181:1-17. doi:10.1016/j.neuroscience.2011.02.035
23. Sidhpura N, Parsons LH. Endocannabinoid-mediated synaptic plasticity and addiction-related behavior. Neuropharmacology (2011) 61(7):1070-87. doi:10.1016/j.neuropharm.2011.05.034
24. Sipe JC, Chiang K, Gerber AL, Beutler E, Cravatt BF. A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc Natl Acad Sci U S A (2002) 99(12):8394-9. doi:10.1073/pnas.082235799
25. Chiang KP, Gerber AL, Sipe JC, Cravatt BF. Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use. Hum Mol Genet (2004) 13(18):2113-9. doi:10.1093/hmg/ddh216
26. Kogan NM, Mechoulam R. Cannabinoids in health and disease. Dialogues Clin Neurosci (2007) 9(4):413-30.
27. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science (1999) 283(5400):401-4. doi:10.1126/science.283.5400.401
28. Hungund BL, Szakall I, Adam A, Basavarajappa BS, Vadasz C. Cannabinoid CB1 receptor knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol-induced dopamine release in the nucleus accumbens. J Neurochem (2003) 84(4):698-704. doi:10.1046/j.1471-4159.2003.01576.x
29. Houchi H, Babovic D, Pierrefiche O, Ledent C, Daoust M, Naassila M. CB1 receptor knockout mice display reduced ethanol-induced conditioned place preference and increased striatal dopamine D2 receptors. Neuropsychopharmacology (2005) 30(2):339-49. doi:10.1038/sj.npp.1300568
30. Caillé S, Parsons LH. SR141716A reduces the reinforcing properties of heroin but not heroin-induced increases in nucleus accumbens dopamine in rats. Eur J Neurosci (2003) 18(11):3145-9. doi:10.1111/j.1460-9568.2003.02961.x
31. Solinas M, Panlilio LV, Antoniou K, Pappas LA, Goldberg SR. The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl) -4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio. J Pharmacol Exp Ther (2003) 306(1):93-102. doi:10.1124/jpet.102.047928
32. Colombo G, Orrù A, Lai P, Cabras C, Maccioni P, Rubio M, et al. The cannabinoid CB1 receptor antagonist, rimonabant, as a promising pharmacotherapy for alcohol dependence: preclinical evidence. Mol Neurobiol (2007) 36(1):102-12. doi:10.1007/s12035-007-0017-y
33. Mereu M, Tronci V, Chun LE, Thomas AM, Green JL, Katz JL, et al. Cocaine-induced endocannabinoid release modulates behavioral and neurochemical sensitization in mice. Addict Biol (2013). doi:10.1111/adb.12080
34. Schlosburg JE, Carlson BLA, Ramesh D, Abdullah RA, Long JZ, Cravatt BF, et al. Inhibitors of endocannabinoid-metabolizing enzymes reduce precipitated withdrawal responses in THC-dependent mice. AAPS J (2009) 11(2):342-52. doi:10.1208/s12248-009-9110-7
35. Ramesh D, Ross GR, Schlosburg JE, Owens RA, Abdullah RA, Kinsey SG, et al. Blockade of endocannabinoid hydrolytic enzymes attenuates precipitated opioid withdrawal symptoms in mice. J Pharmacol Exp Ther (2011) 339(1):173-85. doi:10.1124/jpet.111.181370
36. Viganò D, Grazia Cascio M, Rubino T, Fezza F, Vaccani A, Di Marzo V, et al. Chronic morphine modulates the contents of the endocannabinoid, 2-arachidonoyl glycerol, in rat brain. Neuropsychopharmacology (2003) 28(6):1160-7. doi:10.1038/sj.npp.1300117
37. Caillé S, Parsons LH. Cannabinoid modulation of opiate reinforcement through the ventral striatopallidal pathway. Neuropsychopharmacology (2006) 31(4):804-13. doi:10.1038/sj.npp.1300848
38. Caillé S, Alvarez-Jaimes L, Polis I, Stouffer DG, Parsons LH. Specific alterations of extracellular endocannabinoid levels in the nucleus accumbens by ethanol, heroin, and cocaine self-administration. J Neurosci (2007) 27(14):3695-702. doi:10.1523/JNEUROSCI.4403-06.2007
39. Justinova Z, Solinas M, Tanda G, Redhi GH, Goldberg SR. The endogenous cannabinoid anandamide and its synthetic analog R(+)-methanandamide are intravenously self-administered by squirrel monkeys. J Neurosci (2005) 25(23):5645-50. doi:10.1523/JNEUROSCI.0951-05.2005
40. Justinova Z, Yasar S, Redhi GH, Goldberg SR. The endogenous cannabinoid 2-arachidonoylglycerol is intravenously self-administered by squirrel monkeys. J Neurosci (2011) 31(19):7043-8. doi:10.1523/JNEUROSCI.6058-10.2011
41. Schultz W. Getting formal with dopamine and reward. Neuron (2002) 36(2):241-63. doi:10.1016/S0896-6273(02)00967-4
42. Di Chiara G, Bassareo V, Fenu S, De Luca MA, Spina L, Cadoni C, et al. Dopamine and drug addiction: the nucleus accumbens shell connection. Neuropharmacology (2004) 47(Suppl 1):227-41. doi:10.1016/j.neuropharm.2004.06.032
43. Wise RA. Dopamine and reward: the anhedonia hypothesis 30 years on. Neurotox Res (2008) 14(2-3):169-83. doi:10.1007/BF03033808
44. Di Chiara G. Brain dialysis of neurotransmitters: a commentary. J Neurosci Methods (1990) 34(1-3):29-34. doi:10.1016/0165-0270(90)90039-I
45. Pontieri FE, Tanda G, Di Chiara G. Intravenous cocaine, morphine, and amphetamine preferentially increase extracellular dopamine in the "shell" as compared with the "core" of the rat nucleus accumbens. Proc Natl Acad Sci U S A (1995) 92(26):12304-8. doi:10.1073/pnas.92.26.12304
46. Volkow ND, Wang G-J, Fowler JS, Molina PE, Logan J, Gatley SJ, et al. Cardiovascular effects of methylphenidate in humans are associated with increases of dopamine in brain and of epinephrine in plasma. Psychopharmacology (2003) 166(3):264-70. doi:10.1007/s00213-002-1340-7
47. Fillenz M. In vivo neurochemical monitoring and the study of behaviour. Neurosci Biobehav Rev (2005) 29(6):949-62. doi:10.1016/j.neubiorev.2005.02.003
48. Chang L, Haning W. Insights from recent positron emission tomographic studies of drug abuse and dependence. Curr Opin Psychiatry (2006) 19(3):246-52. doi:10.1097/01.yco.0000218594.46431.2
49. Tanda G, Pontieri FE, Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science (1997) 276(5321):2048-50. doi:10.1126/science.276.5321.2048
50. Lecca D, Cacciapaglia F, Valentini V, Di Chiara G. Monitoring extracellular dopamine in the rat nucleus accumbens shell and core during acquisition and maintenance of intravenous WIN 55,212-2 self-administration. Psychopharmacology (2006) 188(1):63-74. doi:10.1007/s00213-006-0475-3
51. Fadda P, Scherma M, Spano MS, Salis P, Melis V, Fattore L, et al. Cannabinoid self-administration increases dopamine release in the nucleus accumbens. Neuroreport (2006) 17(15):1629-32. doi:10.1097/01.wnr.0000236853.40221.8e
52. Solinas M, Justinova Z, Goldberg SR, Tanda G. Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats. J Neurochem (2006) 98(2):408-19. doi:10.1111/j.1471-4159.2006.03880.x
53. Diana M, Melis M, Muntoni AL, Gessa GL. Mesolimbic dopaminergic decline after cannabinoid withdrawal. Proc Natl Acad Sci U S A (1998) 95(17):10269-73. doi:10.1073/pnas.95.17.10269
54. Tanda G, Loddo P, Di Chiara G. Dependence of mesolimbic dopamine transmission on delta9-tetrahydrocannabinol. Eur J Pharmacol (1999) 376(1-2):23-6. doi:10.1016/S0014-2999(99)00384-2
55. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. 4th ed. London: Academic Press (1998).
56. Fattore L, Viganò D, Fadda P, Rubino T, Fratta W, Parolaro D. Bidirectional regulation of mu-opioid and CB1-cannabinoid receptor in rats self-administering heroin or WIN 55,212-2. Eur J Neurosci (2007) 25(7):2191-200. doi:10.1111/j.1460-9568.2007.05470.x
57. Panlilio LV, Zanettini C, Barnes C, Solinas M, Goldberg SR. Prior exposure to THC increases the addictive effects of nicotine in rats. Neuropsychopharmacology (2013) 38(7):1198-208. doi:10.1038/npp.2013.16
58. Lecca D, Cacciapaglia F, Valentini V, Gronli J, Spiga S, Di Chiara G. Preferential increase of extracellular dopamine in the rat nucleus accumbens shell as compared to that in the core during acquisition and maintenance of intravenous nicotine self-administration. Psychopharmacology (2006) 184(3-4):435-46. doi:10.1007/s00213-005-0280-4
59. Chauvet C, Lardeux V, Goldberg SR, Jaber M, Solinas M. Environmental enrichment reduces cocaine seeking and reinstatement induced by cues and stress but not by cocaine. Neuropsychopharmacology (2009) 34(13):2767-78. doi:10.1038/npp.2009.127
60. Lecca D, Cacciapaglia F, Valentini V, Acquas E, Di Chiara G. Differential neurochemical and behavioral adaptation to cocaine after response contingent and noncontingent exposure in the rat. Psychopharmacology (2007) 191(3):653-67. doi:10.1007/s00213-006-0496-y
61. Lecca D, Valentini V, Cacciapaglia F, Acquas E, Di Chiara G. Reciprocal effects of response contingent and noncontingent intravenous heroin on in vivo nucleus accumbens shell versus core dopamine in the rat: a repeated sampling microdialysis study. Psychopharmacology (2007) 194(1):103-16. doi:10.1007/s00213-007-0815-y
62. Fattore L, Spano M, Melis V, Fadda P, Fratta W. Differential effect of opioid and cannabinoid receptor blockade on heroin-seeking reinstatement and cannabinoid substitution in heroin-abstinent rats. Br J Pharmacol (2011) 163(7):1550-62. doi:10.1111/j.1476-5381.2011.01459.x
63. Tanda G, Munzar P, Goldberg SR. Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nat Neurosci (2000) 3(11):1073-4. doi:10.1038/80577
64. Justinova Z, Tanda G, Redhi GH, Goldberg SR. Self-administration of delta9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys. Psychopharmacology (2003) 169(2):135-40. doi:10.1007/s00213-003-1484-0
65. Justinova Z, Mangieri RA, Bortolato M, Chefer SI, Mukhin AG, Clapper JR, et al. Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates. Biol Psychiatry (2008) 64(11):930-7. doi:10.1016/j.biopsych.2008.08.008
66. Wise RA. Drug-activation of brain reward pathways. Drug Alcohol Depend (1998) 51(1-2):13-22. doi:10.1016/S0376-8716(98)00063-5
67. Wise RA. Brain reward circuitry: insights from unsensed incentives. Neuron (2002) 36(2):229-40. doi:10.1016/S0896-6273(02)00965-0
68. Di Chiara G. Nucleus accumbens shell and core dopamine: differential role in behavior and addiction. Behav Brain Res (2002) 137(1-2):75-114. doi:10.1016/S0166-4328(02)00286-3
69. Wenger T, Ledent C, Tramu G. The endogenous cannabinoid, anandamide, activates the hypothalamo-pituitary-adrenal axis in CB1 cannabinoid receptor knockout mice. Neuroendocrinology (2003) 78(6):294-300. doi:10.1159/000074882
70. Melis M, Pistis M, Perra S, Muntoni AL, Pillolla G, Gessa GL. Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. J Neurosci (2004) 24(1):53-62. doi:10.1523/JNEUROSCI.4503-03.2004
71. Marinelli S, Di Marzo V, Florenzano F, Fezza F, Viscomi MT, van der Stelt M, et al. N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors. Neuropsychopharmacology (2007) 32(2):298-308. doi:10.1038/sj.npp.1301118
72. De Luca MA, Solinas M, Bimpisidis Z, Goldberg SR, Di Chiara G. Cannabinoid facilitation of behavioral and biochemical hedonic taste responses. Neuropharmacology (2012) 63(1):161-8. doi:10.1016/j.neuropharm.2011.10.018
73. Rouzer CA, Ghebreselasie K, Marnett LJ. Chemical stability of 2-arachidonylglycerol under biological conditions. Chem Phys Lipids (2002) 119(1-2):69-82. doi:10.1016/S0009-3084(02)00068-3
74. Carr KD. Augmentation of drug reward by chronic food restriction: behavioral evidence and underlying mechanisms. Physiol Behav (2002) 76(3):353-64. doi:10.1016/S0031-9384(02)00759-X
75. McLaughlin PJ, Winston K, Swezey L, Wisniecki A, Aberman J, Tardif DJ, et al. The cannabinoid CB1 antagonists SR141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats. Behav Pharmacol (2003) 14(8):583-8. doi:10.1097/00008877-200312000-00002
76. Gutierrez-Lopez MD, Llopis N, Feng S, Barrett DA, O'Shea E, Colado MI. Involvement of 2-arachidonoyl glycerol in the increased consumption of and preference for ethanol of mice treated with neurotoxic doses of methamphetamine. Br J Pharmacol (2010) 160(3):772-83. doi:10.1111/j.1476-5381.2010.00720.x
77. Fowler CJ. "The tools of the trade" - an overview of the pharmacology of the endocannabinoid system. Curr Pharm Des (2008) 14(23):2254-65. doi:10.2174/138161208785740126
78. Petrosino S, Ligresti A, Di Marzo V. Endocannabinoid chemical biology: a tool for the development of novel therapies. Curr Opin Chem Biol (2009) 13(3):309-20. doi:10.1016/j.cbpa.2009.04.616
79. Wiskerke J, Irimia C, Cravatt BF, De Vries TJ, Schoffelmeer ANM, Pattij T, et al. Characterization of the effects of reuptake and hydrolysis inhibition on interstitial endocannabinoid levels in the brain: an in vivo microdialysis study. ACS Chem Neurosci (2012) 3(5):407-17. doi:10.1021/cn300036b